Childhood Cancers

Adolescent and young adult patients with cancer face delayed diagnoses, financial hardships and gaps in specialized care, creating a need for tailored support.

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among patients with gliomas.

The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.

Three cycles of chemotherapy were found to face similar results as six cycles among children with retinoblastoma, a type of cancer of the eye.

My daughter's diagnosis of a rare and aggressive brain tumor at 3 years old made me strongly consider whether or not to have her treated with radiation.

During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.

From World Series tickets given to a pediatric patient with cancer to the death of David Harris, known as Cochise in “The Warriors,” at the age of 75, here is this week’s cancer news.

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic leukemia, among other diseases.

When my daughter couldn't express her words while she received treatment for brain cancer, her eyes told me everything I needed to know.

Researchers have identified genetic differences that can make leukemia relapse more or less likely among pediatric patients.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

From Teddi Mellencamp revealing that she had more melanoma spots removed to Isabella Strahan announcing being cancer-free, here’s what’s happening in the oncology space this week.

The Food and Drug Administration recently approved Augtyro for the treatment of patients ages 12 and older with solid tumors harboring an NTRK gene fusion.

The Food and Drug Administration granted a traditional approval to Retevmo for adult and pediatric patients 2 years old and older with advanced or metastatic RET fusion-positive thyroid cancer.

Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions.

Curing childhood cancer, any kind, is no place to be divided.

Ojemda treatment for certain patients with pediatric low-grade glioma is “well-tolerated” and may be safer than traditional options, an expert told CURE®.

The FDA has granted accelerated approval to Ojemda for patients 6 months and older with relapsed or refractory pediatric low-grade glioma with a BRAF fusion or rearrangement, or BRAF V600 mutation.

Lutathera was approved for patients 12 or older with SSTR-positive gastroenteropancreatic neuroendocrine tumors, the FDA announced.

Cancer comes with an awful storm, but the prisms of light can make it a little less worse.

Besponsa provides another — and potentially more effective — option outside of traditional chemotherapy for pediatric patients with relapsed or refractory B-ALL.